NCT03692910View on ClinicalTrials.gov

A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive Episode

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

August 23, 2018

Primary Completion Date

May 21, 2019

Study Completion Date

May 21, 2019

Conditions
Bipolar Disorder IBipolar Disorder IIMajor Depressive Episode
Interventions
DRUG

SAGE-217

SAGE-217 capsule

DRUG

Placebo

SAGE-217 matching placebo capsule

Trial Locations (11)

30030

Sage Investigational Site, Decatur

32256

Sage Investigational Site, Jacksonville

32801

Sage Investigational Site, Orlando

33319

Sage Investigational Site, Lauderhill

63141

Sage Investigational Site, St Louis

72211

Sage Investigational Site, Little Rock

75080

Sage Investigational Site, Richardson

78754

Sage Investigational Site, Austin

91945

Sage Investigational Site, Lemon Grove

92845

Sage Investigational Site, Garden Grove

92868

Sage Investigational Site, Orange

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY